NYSE · Drug Manufacturers - Specialty & Generic · USD
Dr. Reddy's Laboratories Limited (RDY) Stock Analysis
Dr. Reddy's Laboratories Limited (RDY) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RDY Key Statistics
As of Oct 21, 2026Trading
- Open
- $13.24
- Previous Close
- $13.26
- Day's Range
- 13.15–13.23
- 52-Week Range
- 11.36–15.67
- Volume
- 2.11M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.25
Valuation
- Market Cap
- $10.99B
- P/E Ratio
- 29.98
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 20.18
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 1.75
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.03
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.44
Financials (FY)
- Revenue (FY)
- $335.93B+3.19%
- Net Income (FY)
- $42.85B−24.22%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 10.00%
- Shares Outstanding
- 832.99M
- 1-Year Return
- −9.82%
Dividend and dates
- Dividend
- $0.08+0.63%
- Ex-Dividend Date
- July 9, 2026
- Earnings Date
- October 23, 2026
- Avg Volume
- 2.96M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, RDY closed at $13.19, −9.82% over 1 year.
Dr. Reddy's Laboratories Limited (RDY) has a market capitalization of $10.99B.
In fiscal 2025, RDY reported revenue of $335.93B.
RDY Stock Return by Calendar Year
Dr. Reddy's Laboratories Limited (RDY) 10-year return: what $10,000 became
- 1 year
- $10,000 $9,018
- −9.82%
- 5 years
- $10,000 $11,247
- +12.47%
- 10 years
- $10,000 $15,481
- +54.81%
If you had invested $10,000 in Dr. Reddy's Laboratories Limited (RDY) 10 years ago, at the close on October 21, 2016, it would have been worth $15,481 at the close on October 21, 2026: +54.81% in total, +4.47% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −5.39% |
| 2025 | −10.53% |
| 2024 | +14.13% |
| 2023 | +36.48% |
| 2022 | −19.74% |
| 2021 | −7.34% |
| 2020 | +76.80% |
| 2019 | +8.45% |
| 2018 | +1.26% |
| 2017 | −16.43% |
| 2016 (partial year) | −1.07% |
As of October 21, 2026.
RDY Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $335.93B | $42.85B | 12.8% |
| 2024 | $325.54B | $56.54B | 17.4% |
| 2023 | $279.16B | $55.68B | 19.9% |
| 2022 | $245.88B | $45.07B | 18.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $335.93B | $177.26B | $50.12B | $42.85B | 12.8% |
| 2024 | $325.54B | $190.43B | $72.01B | $56.54B | 17.4% |
| 2023 | $279.16B | $163.61B | $65.31B | $55.68B | 19.9% |
| 2022 | $245.88B | $139.34B | $59.05B | $45.07B | 18.3% |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
RDY Dividend History
Dividends per share, 2025 · 1 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $0.08 | 1 | — |
| 2025 | $0.09 | 1 | −5.0% |
| 2024 | $0.10 | 1 | −50.9% |
| 2023 | $0.20 | 2 | +27.6% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $0.08 | 1 | — |
| 2025 | $0.09 | 1 | −5.0% |
| 2024 | $0.10 | 1 | −50.9% |
| 2023 | $0.20 | 2 | +27.6% |
| 2022 | $0.15 | 2 | +12.8% |
| 2021 | $0.14 | 2 | +105.5% |
| 2020 | $0.07 | 1 | +15.0% |
| 2019 | $0.06 | 1 | −3.4% |
| 2018 | $0.06 | 1 | −4.2% |
| 2017 | $0.06 | 1 | — |
Most recent payment: $0.08 per share, ex-dividend July 24, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
RDY Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 97 stocks| Metric | RDY | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/E | 29.98 | 20.31 | 48% above |
| P/S ratio | 0.03 | 2.10 | 0.0x the median |
| Profit margin | 10.00% | −8.14% | 18.1 pts above |
Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Dr. Reddy's Laboratories Limited - Depositary Receipt (RDY) Price Target Decreased by 12.65% to 12.93
FintelDr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B